These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 38672680)

  • 1. Chimeric Antigen Receptor (CAR) T-Cell Therapy in Hematologic Malignancies: Clinical Implications and Limitations.
    Blüm P; Kayser S
    Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late relapse after CAR-T cell therapy for adult patients with hematologic malignancies: A definite evidence from systematic review and meta-analysis on individual data.
    Zinzi A; Gaio M; Liguori V; Cagnotta C; Paolino D; Paolisso G; Castaldo G; Nicoletti GF; Rossi F; Capuano A; Rafaniello C
    Pharmacol Res; 2023 Apr; 190():106742. PubMed ID: 36963592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next-Generation Chimeric Antigen Receptor T-cells.
    Yi D; Gergis M; Hsu J; Yang Y; Bi X; Aljurf M; Gergis U
    Hematol Oncol Stem Cell Ther; 2022 Dec; 15(3):117-121. PubMed ID: 36537905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and Future Perspectives for Chimeric Antigen Receptor T Cells Development in Poland.
    Ślebioda TJ; Stanisławowski M; Kaszubowska L; Zaucha JM; Żmijewski MA
    Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36428480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is it a chimera? A systematic review of the economic evaluations of CAR-T cell therapy - an update.
    Petrou P
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(6):625-650. PubMed ID: 37288738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis.
    Meng J; Wu X; Sun Z; Xun R; Liu M; Hu R; Huang J
    Front Oncol; 2021; 11():698607. PubMed ID: 34381720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Manufacturing Procedures on CAR T Cell Functionality.
    Watanabe N; Mo F; McKenna MK
    Front Immunol; 2022; 13():876339. PubMed ID: 35493513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strengthening the CAR-T cell therapeutic application using CRISPR/Cas9 technology.
    Sadeqi Nezhad M; Yazdanifar M; Abdollahpour-Alitappeh M; Sattari A; Seifalian A; Bagheri N
    Biotechnol Bioeng; 2021 Oct; 118(10):3691-3705. PubMed ID: 34241908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular Therapy Updates in B-Cell Lymphoma: The State of the CAR-T.
    Crees ZD; Ghobadi A
    Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic Evaluations of Chimeric Antigen Receptor T-Cell Therapies for Hematologic and Solid Malignancies: A Systematic Review.
    Thavorn K; Thompson ER; Kumar S; Heiskanen A; Agarwal A; Atkins H; Shorr R; Hawrysh T; Chan KK; Presseau J; Ollendorf DA; Graham ID; Grimshaw JM; Lalu MM; Nochaiwong S; Fergusson DA; Hutton B; Coyle D; Kekre N
    Value Health; 2024 Aug; 27(8):1149-1173. PubMed ID: 38641057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric antigen receptor T-cell therapy-induced nervous system toxicity: a real-world study based on the FDA Adverse Event Reporting System database.
    Ren X; Zhang G; Li G; Wang Y
    BMC Cancer; 2024 Jan; 24(1):10. PubMed ID: 38166723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Implementation of Chimeric Antigen Receptor (CAR) T-cell Therapy in Pediatric Patients: Where Did We Come From, Where Are We Now, and Where are We Going?
    Knight E T; Oluwole O; Kitko C
    Clin Hematol Int; 2024; 6(1):96-115. PubMed ID: 38817691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US.
    Ghanem B; Shi L
    BioDrugs; 2022 Nov; 36(6):773-780. PubMed ID: 36167952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA-approved CAR T-cell Therapy: A Decade of Progress and Challenges.
    Ong MZ; Kimberly SA; Lee WH; Ling M; Lee M; Tan KW; Foo JB; Yow HY; Sellappans R; Hamzah S
    Curr Pharm Biotechnol; 2024; 25(11):1377-1393. PubMed ID: 39034731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurotoxicity associated with chimeric antigen receptor T-cell therapy: a real-world study leveraging the FDA Adverse Event Reporting System.
    Zhai Y; Yuan L; Fang S; Liu S; Ye X; Shi W; Cao Y; He J; Hu F; Xu F
    Expert Opin Drug Saf; 2024 Oct; ():1-9. PubMed ID: 39410883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies.
    Al-Juhaishi T; Ahmed S
    Curr Hematol Malig Rep; 2021 Feb; 16(1):32-39. PubMed ID: 33630232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma.
    Nath K; Wudhikarn K; Alarcon Tomas A; Perales MA
    Expert Opin Drug Saf; 2023 Jan; 22(1):5-15. PubMed ID: 36737060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Progress in CAR-T Cell Therapy for Hematological Malignancies.
    Han D; Xu Z; Zhuang Y; Ye Z; Qian Q
    J Cancer; 2021; 12(2):326-334. PubMed ID: 33391429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAR T Cells.
    Nair R; Westin J
    Adv Exp Med Biol; 2021; 1342():297-317. PubMed ID: 34972970
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.